

Indian Journal of Pharmaceutical Sciences

Scientific Publication of the Indian Pharmaceutical Association

Indexed in Ind MED, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, Chemical Abstracts.

Volume 69

Number 5

September-October 2007

CONTENTS

REVIEW ARTICLES

- Recent Trends in Drug-Likeness Prediction: A Comprehensive Review of *In Silico* Methods**
R. U. KADAM AND N. ROY 609-615
- Biodegradable Polymers: Which, When and Why?**
V. B. KOTWAL, MARIA SAIFEE, NAZMA INAMDAR AND KIRAN BHISE 616-625

RESEARCH PAPERS

- Strong Cation Exchange Resin for Improving Physicochemical Properties and Sustaining Release of Ranitidine Hydrochloride**
S. KHAN, A. GUHA, P. G. YEOLE, AND P. KATARIYA 626-632
- Novel Co-Processed Excipients of Mannitol and Microcrystalline Cellulose for Preparing Fast Dissolving Tablets of Glipizide**
S. JACOB, A. A. SHIRWAIKAR, A. JOSEPH, K. K. SRINIVASAN 633-639
- Formulation and Optimization of Directly Compressible Isoniazid Modified Release Matrix Tablet**
M. C. GOHEL, R. K. PARIKH, M. N. PADSHALA, K. G. SARVAIYA AND D. G. JENA 640-645
- Effect of Casting Solvent and Polymer on Permeability of Propranolol Hydrochloride Through Membrane Controlled Transdermal Drug Delivery System**
T. E. G. K. MURTHY AND V. S. KISHORE 646-650
- Preparation of Mucoadhesive Microspheres for Nasal Delivery by Spray Drying**
MAHALAXMI RATHANANAND, D. S. KUMAR, A. SHIRWAIKAR, RAVI KUMAR, D. SAMPATH KUMAR AND R. S. PRASAD 651-657
- Effect of Polymers on Crystallo-co-agglomeration of Ibuprofen-Paracetamol: Factorial Design**
A. PAWAR, A. R. PARADKAR, S. S. KADAM AND K. R. MAHADIK 658-664
- Synthesis and Antimicrobial Evaluation of Some Novel 2-Imino-3-(4'-carboxamido pyridyl)-5-Arylidene-4-Thiazolidinones and their Brominated Derivatives**
P. MISHRA, T. LUKOSE AND S. K. KASHAW 665-668
- Measurement of Urine and Plasma Oxalate with Reusable Strip of Amaranthus Leaf Oxalate Oxidase**
NISHA SHARMA, MINAKSHI SHARMA, V. KUMAR AND C. S. PUNDIR 669-673

SHORT COMMUNICATIONS

- Simultaneous HPLC Estimation of Omeprazole and Domperidone from Tablets**
LAKSHMI SIVASUBRAMANIAN AND V. ANILKUMAR 674-676
- Isolation and Evaluation of Fenugreek Seed Husk as a Granulating Agent**
AMELIA AVACHAT, K. N. GUJAR, V. B. KOTWAL AND SONALI PATIL 676-679
- Synthesis and *In Vitro* Efficacy of some Halogenated Imine Derivatives as Potential Antimicrobial Agents**
A. K. HALVE, DEEPTI BHADAURIA, B. BHASKAR, R. DUBEY AND VASUDHA SHARMA 680-682
- Simultaneous Spectrophotometric Estimation of Atorvastatin Calcium and Ezetimibe in Tablets**
S. S. SONAWANE, A. A. SHIRKHEDKAR, R. A. FURSULE AND S. J. SURANA 683-684
- High Performance Thin Layer Chromatographic Estimation of Lansoprazole and Domperidone in Tablets**
J. V. SUSHEEL, M. LEKHA AND T. K. RAVI 684-686
- Antimicrobial Activity of *Helicteres isora* Root**
S. VENKATESH, K. SAILAXMI, B. MADHAVA REDDY AND MULLANGI RAMESH 687-689
- Synthesis and Antibacterial Activity of 2-phenyl-3,5-diphenyl (substituted) -6-aryl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d]thiazoles**
S. K. SAHU, S. K. MISHRA, R. K. MOHANTA, P. K. PANDA AND MD. AFZAL AZAM 689-692

- Simultaneous Estimation of Aceclofenac, Paracetamol and Chlorzoxazone in Tablets**
G. GARG, SWARNLATA SARAF AND S. SARAF 692-694
- Reverse Phase High Performance Liquid Chromatography Method for Estimation of Ezetimibe in Bulk and Pharmaceutical Formulations**
S. K. AKMAR, LATA KOTHAPALLI, ASHA THOMAS, SUMITRA JANGAM AND A. D. DESHPANDE 695-697
- Synthesis and Antiinflammatory Activity of N-Aryl Anthranilic Acid and its Derivatives**
J. K. JOSHI, V. R. PATEL, K. PATEL, D. RANA, K. SHAH, RONAK PATEL AND RAJESH PATEL 697-699
- RP-HPLC Method for the Determination of Atorvastatin calcium and Nicotinic acid in Combined Tablet Dosage Form**
D. A. SHAH, K. K. BHATT, R. S. MEHTA, M. B. SHANKAR AND S. L. BALDANIA 700-703
- Determination of Etoricoxib in Pharmaceutical Formulations by HPLC Method**
H. M. PATEL, B. N. SUHAGIA, S. A. SHAH AND I. S. RATHOD 703-705

Proceedings of the Symposium on Advances in Pulmonary and Nasal Drug Delivery, October 2007, Mumbai

- Albumin Microspheres of Fluticasone Propionate Inclusion Complexes for Pulmonary Delivery**
A. A. LOHADE, D. J. SINGH, J. J. PARMAR, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD AND R. V. GAIKWAD 707-709
- Design and Development of Thermoreversible Mucoadhesive Microemulsion for Intranasal Delivery of Sumatriptan Succinate**
R. S. BHANUSHALI AND A. N. BAJAJ 709-712
- Preparation and Characterization of Chitosan Nanoparticles for Nose to Brain Delivery of a Cholinesterase inhibitor**
BHAVNA, V. SHARMA, M. ALI, S. BABOOTA AND J. ALI 712-713
- Poloxamer Coated Fluticasone Propionate Microparticles for Pulmonary Delivery; *In Vivo* Lung Deposition and Efficacy Studies**
D. J. SINGH, J. J. PARMAR, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD, AND R. V. GAIKWAD 714-715
- Sustained Release Budesonide Liposomes: Lung Deposition and Efficacy Evaluation**
J. J. PARMAR, D. J. SINGH, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD AND R. V. GAIKWAD 716-717
- Generation of Budesonide Microparticles by Spray Drying Technology for Pulmonary Delivery**
S. R. NAIKWADE AND A. N. BAJAJ 717-721
- Microemulsion of Lamotrigine for Nasal Delivery**
A. J. SHENDE, R. R. PATIL AND P. V. DEVARAJAN 721-722
- Development of a pMDI Formulation Containing Budesonide**
E. ROBINS, G. BROUET AND S. PRIOLKAR 722-724
- Development of a pMDI Formulation Containing Salbutamol**
E. ROBINS, G. WILLIAMS AND S. PRIOLKAR 724-726
- Aqua Triggered *In Situ* Gelling Microemulsion for Nasal Delivery**
R. R. SHELKE AND P. V. DEVARAJAN 726-727
- In vivo* Performance of Nasal Spray Pumps in Human Volunteers By SPECT-CT Imaging**
S. A. HAZARE, M. D. MENON, P. S. SONI, G. WILLIAMS AND G. BROUET 728-729
- Nasal Permeation Enhancement of Sumatriptan Succinate through Nasal Mucosa**
S. S. SHIDHAYE, N. S. SAINDANE, P. V. THAKKAR, S. B. SUTAR AND V. J. KADAM 729-731
- Formulation Development of Eucalyptus Oil Microemulsion for Intranasal Delivery**
N. G. TIWARI AND A. N. BAJAJ 731-733

Simultaneous Estimation of Aceclofenac, Paracetamol and Chlorzoxazone in Tablets

G. GARG, SWARNLATA SARAF AND S. SARAF*

Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur - 492 010, India

The combination of aceclofenac, paracetamol and chlorzoxazone is emerging as one of the widely prescribed combination in single dosage form. Aceclofenac is a typical Cox-2 inhibitor in combination with muscle relaxant chlorzoxazone and a traditional antipyretic drug paracetamol. Literature revealed that there is no single method for the simultaneous estimation of all these drugs in tablet dosage forms, which prompted us to develop a simple, rapid, accurate, economical and sensitive spectrophotometric method. The simultaneous estimation method is based on the additivity of absorbances, for the determination of aceclofenac, paracetamol and chlorzoxazone in

***For correspondence**

E-mail: rsofiop_gg@rediffmail.com

tablet formulation. The absorption maxima of the drugs found to be at 276 nm, 282 nm and 248 nm respectively for aceclofenac, chlorzoxazone and paracetamol in methanol. All three drugs obeyed the Beer Lambert's law in the concentration range of 2-20 µg/ml. The accuracy and reproducibility of the proposed method was statistically validated by recovery studies.

Key words: Simultaneous ace para and chloro

Aceclofenac is 2[(2,6-dichlorophenyl)amino]benzoic acid carboxymethyl ester is an analgesic and non-steroidal antiinflammatory drug; paracetamol (4-hydroxy acetanilide) is used as an analgesic and anti pyretic drug and chlorzoxazone is 5-chloro-2-benzoxazolol is a commonly prescribed muscle relaxant. Aceclofenac is official in BP¹, paracetamol in BP and IP^{2,3} and chlorzoxazone in USP⁴. BP suggests a potentiometric assay method for aceclofenac in bulk drugs. The IP and BP both suggest titrimetric and UV spectrophotometric assay method for paracetamol in bulk and tablet formulations. Literature survey revealed that HPLC⁵, densitometric⁶, spectrofluorimetric⁷ and colorimetric⁸ methods have been reported for the estimation of aceclofenac in pharmaceutical dosage forms. With the advancement in the field of analytical chemistry and software technology different methods have been developed for simultaneous estimation of combination dosage forms. Though the combination is widely prescribed, no simultaneous method is reported for the estimation of the drugs in combined dosage forms. This prompted us to develop simple, rapid, accurate, economical and sensitive spectrophotometric simultaneous method.

The Shimadzu Pharmaspec 1700 UV/Vis spectrophotometer with 10 mm matched quartz cells was used for experiments. The chemicals used were of analytical grade. The commercially available tablets of aceclofenac, paracetamol and chlorzoxazone in combination were procured from local market. Aceclofenac, received as gift sample from Aristo Pharma Ltd., paracetamol (BDH) and chlorzoxazone from Mankind Pharma were used as such without further purification.

Standard stock solution of aceclofenac, paracetamol and chlorzoxazone were prepared separately by dissolving 100 mg each (accurately weighed) of standard aceclofenac, paracetamol and chlorzoxazone in methanol and made up the volume up to 100 ml with same solvent. Working standard solutions (10 µg/ml) (A), (B) and (C) were further prepared by taking 1 ml of stock solution of each drug solution in

100 ml volumetric flasks separately and made up the volume up to the mark with methanol.

Overlain spectra of standard solutions of aceclofenac, paracetamol and chlorzoxazone were scanned (fig. 1). Aceclofenac shows absorption maxima at 276 nm, paracetamol shows at 248 nm and chlorzoxazone at 282 nm. The calibration curves for each were prepared in the concentration range of 2-20 µg/ml at each wavelength i.e. 276 nm, 248 nm and 282 nm. The absorptivity coefficients were determined for all the drugs at all the wavelengths and following equations were made. $A_1 = 306.64 C_x + 163.16 C_y + 251.4 C_z$..(1), $A_2 = 109.52 C_x + 908.22 C_y$..(2) and $A_3 = 293.77 C_x + 135.58 C_y + 325.52 C_z$.. (3), where A_1 , A_2 and A_3 are absorbances at 276 nm, 248 nm and 282 nm, respectively and C_x , C_y and C_z are concentrations of aceclofenac, paracetamol and chlorzoxazone respectively.

Tablet estimation was done on of two brands, Dolokind-MR (Mankind Pharma, Delhi) and Morcet-MR (Moraceae Lab, Luknow). Twenty tablets were weighed and crushed to a fine powder. Powder equivalent to 65 mg of paracetamol, 20 mg of aceclofenac and 50 mg chlorzoxazone (tablet contains 325 mg paracetamol, 100 mg aceclofenac and 250 mg chlorzoxazone) was extracted quantitatively with (4×20) ml of methanol and volume was made up to 100 ml. Insoluble excipients were separated by filtration. The filtrate was further diluted to get final concentration of both the drugs in the linearity range.




Fig. 1: Overlain spectra of aceclofenac, paracetamol and chlorzoxazone in methanol

Ace- spectrum of aceclofenac, λ_{max} 276 nm, **Para-** spectrum of paracetamol, λ_{max} 248 nm, **Chlor-** spectrum of chlorzoxazone, λ_{max} 282 nm

TABLE 1: COMPILATION OF RESULTS OF STATISTICAL ANALYSIS OF COMMERCIAL FORMULATIONS

Tablet brand	Tablet component	Label claim* (mg/tab)	Amount found* (mg/tab)	SD*	%RSD*	SE*	't' Calc.*
A	Aceclofenac	100	99.47	0.2218	0.0796	0.6174	0.3514
	Paracetamol	325	323.87	0.0049	0.0489	0.2315	0.8251
	Chlorzoxazone	250	248.14	0.2876	0.0214	0.1479	0.3954
B	Aceclofenac	100	99.14	0.0868	0.0014	0.0157	0.8471
	Paracetamol	325	324.78	0.0789	0.0127	0.1896	0.2354
	Chlorzoxazone	250	249.04	0.2156	0.0046	0.2310	0.9623

*Average of six determinations. Theoretical 't' values are at 95% confidence level for (n-1) degrees of freedom. 't' (0.05,5)= 2.571. SD is standard deviation; % RSD is percent relative standard deviation and SE is standard error.

TABLE 2: COMPILATION OF RESULTS OF DRUG RECOVERY STUDY

Tablet brand	Recovery level (Added amount)	Percent recovery + SD*		
		Aceclofenac	Paracetamol	Chlorzoxazone
A	50%	99.47+0.0234	99.85+0.0150	99.34+0.1054
B		99.14+0.0158	99.90+0.0070	99.04+0.2163
A	100%	98.94+0.1023	99.96+0.0134	99.09+0.1897
B		99.12+0.0189	99.59+0.0698	98.98+0.1247
A	150%	99.87+0.0146	99.21+0.0197	99.01+0.1235
B		99.29+0.0698	99.35+0.0524	99.27+0.1754

*Average of six determinations, SD is standard deviation

Absorbance was noted at the selected wavelengths and concentrations were determined by using the Eqns. 1, 2 and 3.

The method was found to be accurate, simple and rapid, for routine simultaneous analysis of the formulations without prior separation. The content of the aceclofenac, paracetamol and chlorzoxazone was directly found from the Eqns. 1, 2 and 3 using matrices (Cramer's rule).

$$x^D = \frac{a_1x+b_1y+c_1z}{a_2x+b_2y+c_2z} \frac{b_1 c_1 d_1}{b_2 c_2 d_2} = \frac{d_1 b_1 c_1}{d_2 b_2 c_2} = Dx,$$

$$a_3x+b_3y+c_3z \frac{b_1 c_1 d_1}{b_3 c_3 d_3} = Dx,$$

similarly using the same approach the other determinant Dy and Dz can also be found out.

The reproducibility, repeatability and accuracy of the proposed method were found to be satisfactory which is evidenced by low values of standard deviation, percent relative standard deviation and standard error (Table 1). The percent range of error (within 95% confidence limits) showed precision of the method. The accuracy and reproducibility of the proposed method was confirmed by recovery experiments, performed by adding known amount of the drugs to the pre analyzed formulations and reanalyzing the mixture by proposed method (Table 2). The percent recovery obtained indicates non-interference from the excipients used in the formulations. Thus the method developed in the present investigation found to be simple, sensitive, accurate and precise and can be successfully applied for the simultaneous estimation

of aceclofenac, paracetamol and chlorzoxazone in tablets.

ACKNOWLEDGEMENTS

The authors wish to thank Director, Institute of Pharmacy, Pt. Ravishankar Shukla University Raipur (CG) for providing necessary facilities, also thanks to Aristo Pharma Ltd., Mandideep and Mankind Pharma Delhi for providing the authentic sample of drugs.

REFERENCES

1. British Pharmacopoeia, Vol. I, London: Her Majesty's Stationary office; 1998; p. 33.
2. British Pharmacopoeia, Vol. II, London: Her Majesty's Stationary office; 1998; p. 1854.
3. Indian Pharmacopoeia, Vol. II, New Delhi: the controller of publications, Govt. of India; 1996, p. 554.
4. United State Pharmacopoeia XXVII22, Rockville, MD: United States Pharmacopoeial Convention INC; 2004, p. 441.
5. Hinz B, Auge D, Rau T, Rietbrock S, Brune K and Werner U. Simultaneous Determination of Aceclofenac and Three of its Metabolites in Human Plasma by High-Performance Liquid Chromatography. *Biomed Chromatogr* 2003; 17: 268.
6. El-Saharty YS, Refaat M and el-Khateeb SZ. Stability Indicating Spectrophotometric and Densitometric Methods for Determination of Aceclofenac. *Drug Develop Int Pharm* 2002; 28: 571.
7. El-Kousy NM. Spectrophotometric and Spectrofluorimetric Determination of Etodolac and Aceclofenac. *J Pharm Biomed Anal* 1999; 20: 185.
8. Zawilla NH, Mohammad MA, el-Kousy NM and el-Moghazy AS. Determination of Aceclofenac in Bulk and Pharmaceutical Formulations. *J Pharm Biomed Anal* 2002; 27: 243.

Accepted 13 October 2007

Revised 16 April 2007

Received 10 March 2006

Indian J. Pharm. Sci., 2007, 69 (5): 692-694